Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: A cause of the tumor uptake in PET

Journal of Nuclear Medicine

Volumn 53, Issue 8, 2012, Pages 1253-1261

  Wiriyasermkul, Pattama ^a,b   Nagamori, Shushi ^a   Tominaga, Hideyuki ^c   Oriuchi, Noboru ^c   Kaira, Kyoichi ^c   Nakao, Hidekazu ^d   Kitashoji, Takeru ^d   Ohgaki, Ryuichi ^a   Tanaka, Hidekazu ^a   Endou, Hitoshi ^b   Endo, Keigo ^c   Sakurai, Hiroyuki ^b   Kanai, Yoshikatsu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Nard Institute Ltd   (Japan)

Author keywords

3 fluoro L methyl tyrosine (FAMT); Amino acid transporter; Cancer; PET

Indexed keywords

2 FLUORO ALPHA METHYLTYROSINE; 2 FLUOROTYROSINE; 3 FLUORO ALPHA METHYLTYROSINE; 3 FLUORO ALPHA METHYLTYROSINE F 18; 3 IODO ALPHA METHYLTYROSINE; AMINO ACID TRANSPORTER; FLUOROTYROSINE; L TYPE AMINO ACID TRANSPORTER 1; L TYPE AMINO ACID TRANSPORTER 2; LEUCINE C 14; METHIONINE; METIROSINE; O (2 FLUOROETHYL)TYROSINE; RADIOPHARMACEUTICAL AGENT; TYROSINE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ANIMAL CELL; ARTICLE; CELL TRANSPORT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSPORT KINETICS; TUMOR; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; FLUORINE RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LEUCINE; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TYROSINE; UP-REGULATION;

EID: 84864755188     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.103069     Document Type: Article

References (40)

1. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med. 2008;49 (suppl 2):43S-63S. (Pubitemid 351948036)
2. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363-1378. (Pubitemid 29467035)
3. Jager PL, VaalburgW, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445. (Pubitemid 32207394)
4. 11C]methionine using whole-body positron emission tomography. Eur J Nucl Med. 1998;25:629-633.
5. 18F-fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging. 2003;30:519-524.
6. 18F-α-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169-175.
7. 18F-α-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40:399-405.
8. Inoue T, Koyama K, Oriuchi N, et al. Detection of malignant tumors: whole-body PET with fluorine 18 α-methyl tyrosine versus FDG-preliminary study. Radiology. 2001;220:54-62. (Pubitemid 32577959)
9. Kaira K, Oriuchi N, Otani Y, et al. Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369-6378. (Pubitemid 350075026)
10. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009;50:1770-1776.
11. 18F-FDG PET-CT: a clinicopathological study. Int J Cancer. 2009; 124:1152-1160.
12. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629-23632. (Pubitemid 28435687)
13. +-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999;274:19745-19751.
14. Babu E, Kanai Y, Chairoungdua A, et al. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem. 2003;278:43838-43845. (Pubitemid 37346012)
15. Bodoy S, Martin L, Zorzano A, Palacin M, Estevez R, Bertran J. Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem. 2005;280: 12002-12011. (Pubitemid 40418518)
16. Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab. 2001;2:339-354. (Pubitemid 33133979)
17. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254-266. (Pubitemid 41065034)
18. Nawashiro H, Otani N, Shinomiya N, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119: 484-492. (Pubitemid 43955699)
19. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742-748. (Pubitemid 351272621)
20. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer. 2009;66:120-126.
21. Ooi T, Takeuchi M, Kameda M, Maruoka K. Practical catalytic enantioselective synthesis of α,α-dialkyl-α-amino acids by chiral phase-transfer catalysis. J Am Chem Soc. 2000;122:5228-5229. (Pubitemid 30354295)
22. Morimoto E, Kanai Y, Kim DK, et al. Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters. J Pharmacol Sci. 2008;108:505-516.
23. Oda K, Hosoda N, Endo H, et al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010;101:173-179.
24. Kim DK, Kanai Y, Choi HW, et al. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta. 2002;1565:112-121.
25. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61:729-737. (Pubitemid 34273151)
26. Bröer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev. 2008;88:249-286.
27. 125I-iodo-α-methyl- L-tyrosine membrane transport in human L-type amino acid transporters. J Nucl Med. 2003;44:244-246.
28. 18F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med. 2007;48:2063-2071.
29. +/monocarboxylate transporters. J Biol Chem. 2001;276:17221-17228.
30. 123I]IMT) transport in human GOS3 glioma cells. Nucl Med Biol. 2001;28:293-297.
31. Shikano N, Kawai K, Nakajima S, et al. Renal accumulation and excretion of radioiodinated 3-iodo-α-methyl-L-tyrosine. Ann Nucl Med. 2004;18:263-270. (Pubitemid 38899677)
32. 0,+. J Biol Chem. 1999;274:23740-23745.
33. Lahoutte T, Caveliers V, Camargo SM, et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med. 2004;45:1591-1596. (Pubitemid 47618515)
34. 18F]fluoroethyl)-L- tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging. 2002;29:1039-1046.
35. 3H-deoxyglucose in brain abscesses. J Nucl Med. 2007;48:2056-2062.
36. Ishiwata K, Kubota K, Murakami M, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med. 1993;34:1936-1943. (Pubitemid 23331262)
37. Ishiwata K, Enomoto K, Sasaki T, et al. A feasibility study on L-[1-carbon-11] tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med. 1996;37:279-285.
38. Langen KJ, Jarosch M, Muhlensiepen H, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol. 2003;30:501-508. (Pubitemid 36776519)
39. 18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging. 2006;33: 932-939.
40. 123I-iodo-α- methyl-L-tyrosine SPECT in brain tumors. J Nucl Med. 2004;45:374-381.